For example, L1CAM positivity ranged from 2 to 100% in neurofibroma, 24–95% in serous carcinoma of the ovary, 24–96% in malignant melanoma, 0–56% in colorectal adenocarcinoma, 3–100% in endometrial cancer, 21–100% in papillary renal cell carcinoma (RCC), 2–93% in ductal adenocarcinoma of the pancreas, 11–63% in hepatocellular carcinoma and 2–74% in gastrointestinal stromal tumor (GIST) (Table 3). This evidence concerns the gene L1CAM and pancreatic ductal adenocarcinoma.